161 related articles for article (PubMed ID: 21327450)
21. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
Toi M; Iwata H; Fujiwara Y; Ito Y; Nakamura S; Tokuda Y; Taguchi T; Rai Y; Aogi K; Arai T; Watanabe J; Wakamatsu T; Katsura K; Ellis CE; Gagnon RC; Allen KE; Sasaki Y; Takashima S
Br J Cancer; 2009 Nov; 101(10):1676-82. PubMed ID: 19844234
[TBL] [Abstract][Full Text] [Related]
22. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
23. Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
Jiao XD; Ding C; Zang YS; Yu G
BMC Cancer; 2018 Feb; 18(1):206. PubMed ID: 29463236
[TBL] [Abstract][Full Text] [Related]
24. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
25. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib: a sword with two edges.
Kopper L
Pathol Oncol Res; 2008 Mar; 14(1):1-8. PubMed ID: 18409020
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Taskar KS; Rudraraju V; Mittapalli RK; Samala R; Thorsheim HR; Lockman J; Gril B; Hua E; Palmieri D; Polli JW; Castellino S; Rubin SD; Lockman PR; Steeg PS; Smith QR
Pharm Res; 2012 Mar; 29(3):770-81. PubMed ID: 22011930
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.
Kim JM; Miller JA; Kotecha R; Chao ST; Ahluwalia MS; Peereboom DM; Mohammadi AM; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Abraham J; Moore H; Budd GT; Suh JH
Neuro Oncol; 2019 May; 21(5):659-668. PubMed ID: 30726965
[TBL] [Abstract][Full Text] [Related]
30. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
[TBL] [Abstract][Full Text] [Related]
31. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
Blackwell KL; Pegram MD; Tan-Chiu E; Schwartzberg LS; Arbushites MC; Maltzman JD; Forster JK; Rubin SD; Stein SH; Burstein HJ
Ann Oncol; 2009 Jun; 20(6):1026-31. PubMed ID: 19179558
[TBL] [Abstract][Full Text] [Related]
32. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Azim HA; Azim HA
Future Oncol; 2012 Feb; 8(2):135-44. PubMed ID: 22335578
[TBL] [Abstract][Full Text] [Related]
33. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
34. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
35. Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib.
Park Y; Kim H; Kim EH; Suh CO; Lee S
Cancer Res Treat; 2016 Jan; 48(1):403-8. PubMed ID: 25715765
[TBL] [Abstract][Full Text] [Related]
36. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
de Azambuja E; Zardavas D; Lemort M; Rossari J; Moulin C; Buttice A; D'Hondt V; Lebrun F; Lalami Y; Cardoso F; Sotiriou C; Gil T; Devriendt D; Paesmans M; Piccart-Gebhart M; Awada A
Ann Oncol; 2013 Dec; 24(12):2985-9. PubMed ID: 24013582
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
Burstein HJ; Storniolo AM; Franco S; Forster J; Stein S; Rubin S; Salazar VM; Blackwell KL
Ann Oncol; 2008 Jun; 19(6):1068-74. PubMed ID: 18283035
[TBL] [Abstract][Full Text] [Related]
39. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE
Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
